Denali Therapeutics Inc. Stock price

Equities

DNLI

US24823R1059

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
20.77 USD +4.48% Intraday chart for Denali Therapeutics Inc. -2.44% -3.22%
Sales 2024 * 64.83M Sales 2025 * 120M Capitalization 2.96B
Net income 2024 * -411M Net income 2025 * -442M EV / Sales 2024 * 22.6 x
Net cash position 2024 * 1.49B Net cash position 2025 * 1.27B EV / Sales 2025 * 14.1 x
P/E ratio 2024 *
-7.85 x
P/E ratio 2025 *
-7.71 x
Employees 445
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.11%
More Fundamentals * Assessed data
Dynamic Chart
Denali Therapeutics Files Prospectus for Secondary Offering MT
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors CI
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study MT
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint DJ
Sanofi: failure of a phase 2 trial against ALS CF
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing MT
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium CI
Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium CI
Transcript : Denali Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 10:30 AM
More news
1 day+4.48%
1 week-2.44%
Current month+5.01%
1 month-11.05%
3 months-6.48%
6 months-3.53%
Current year-3.22%
More quotes
1 week
19.35
Extreme 19.35
21.04
1 month
19.24
Extreme 19.24
21.87
Current year
15.49
Extreme 15.49
23.52
1 year
15.45
Extreme 15.45
33.31
3 years
15.45
Extreme 15.45
79.70
5 years
12.39
Extreme 12.39
93.94
10 years
12.32
Extreme 12.32
93.94
More quotes
Managers TitleAgeSince
Founder 50 13-10-13
Founder 48 13-10-13
Chief Tech/Sci/R&D Officer - 19-12-31
Members of the board TitleAgeSince
Chairman 75 15-03-31
Director/Board Member 71 15-03-31
Director/Board Member 66 15-03-31
More insiders
Date Price Change Volume
24-03-27 20.77 +4.48% 801,711
24-03-26 19.88 +0.05% 1,246,396
24-03-25 19.87 +1.27% 932,394
24-03-22 19.62 -6.57% 992,823
24-03-21 21 -1.36% 1,173,255

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company's clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company's product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The Company engineers its product candidates to cross the BBB, and act directly in the brain.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
20.77 USD
Average target price
42.8 USD
Spread / Average Target
+106.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Denali Therapeutics Inc. - Nasdaq